Oncology News | pharmaphorum

News

Opdivo and chemotherapy combo increases survival in lung can...

Lung cancer drug Opdivo administered with chemotherapy has been shown to boost survival rates in patients with resectable non-small cell lung cancer (NSCLC).

News

Blackstone revs up Autolus' CAR with $250m fuel injection

Private equity firm Blackstone has agreed to provide up to $250 million in financing to UK biotech Autolus Therapeutics, to help it take acute lymphoblastic leukaemia (ALL) CAR-T therapy ob

News

Trial flop busts Deciphera's blockbuster hopes for Qinlock

Shares in Deciphera Pharma went into freefall on Friday after top-line results of a phase 3 trial of its Qinlock in rare cancer gastrointestinal stromal tumour (GIST) dashed its hopes of mo

News

EMA starts review of Enhertu for HER2+ gastric cancer

The EMA has started its review of AstraZeneca and Daiichi Sankyo's Enhertu for a second indication, as a second-line treatment for HER2-positive gastric cancer.

News

Novartis' 'wild card' drug Scemblix gets FDA nod for leukaem...

Novartis has claimed FDA approval for one of its 'wild card' drugs – Scemblix – a first-in-class STAMP inhibitor for patients with previously-treated chronic myeloid leukaemia (CML).

News

First launch for Daiichi Sankyo's oncolytic virus Delytact i...

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer.

Opdivo and chemotherapy combo increases survival in lung can...

Blackstone revs up Autolus' CAR with $250m fuel injection

Trial flop busts Deciphera's blockbuster hopes for Qinlock

EMA starts review of Enhertu for HER2+ gastric cancer

Novartis' 'wild card' drug Scemblix gets FDA nod for leukaem...

First launch for Daiichi Sankyo's oncolytic virus Delytact i...

FDA orders blindness risk warning to GLP-1 agonist labels

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks